US00507W2061 - Common Stock
ACTINIUM PHARMACEUTICALS INC
NYSEARCA:ATNM (5/14/2024, 7:21:07 PM)
After market: 10.62 +0.73 (+7.38%)9.89
+1.03 (+11.63%)
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. The company is headquartered in New York City, New York and currently employs 49 full-time employees. The company went IPO on 2014-03-26. The firm is focused on developing and commercializing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs. The firm develops and markets medicines for relapsed or refractory cancer patients who are treated primarily in large quaternary care hospitals and their catchment areas. Its Iomab-B and Actimab-A product candidates fill the major unmet medical needs in relapsed or refractory acute myeloid leukemia (r/r AML). Iomab-B is a targeted bridging therapy that provides both disease control and conditioning in one agent. Actimab-A is a targeted therapy for fit patients that has demonstrated an impressive extension in survival in a proof-of-concept study and is poised for advanced development in collaboration with the National Cancer Institute (NCI).
ACTINIUM PHARMACEUTICALS INC
100 Park Ave., 23Rd Floor
New York City NEW YORK 10016
P: 16466773870
CEO: Sandesh Seth
Employees: 49
Website: https://www.actiniumpharma.com/
Many of these cheap biotech stocks are on their way to achieving FDA approval for their drugs to enter the market.
ATNM stock results show that Actinium Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate.
Here you can normally see the latest stock twits on ATNM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: